ASTELLAS PHARMA UNSP.ADR (YPHA) - Net Assets
Based on the latest financial reports, ASTELLAS PHARMA UNSP.ADR (YPHA) has net assets worth €1.51 Trillion EUR (≈ $1.77 Trillion USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.34 Trillion ≈ $3.90 Trillion USD) and total liabilities (€1.83 Trillion ≈ $2.14 Trillion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore YPHA cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.51 Trillion |
| % of Total Assets | 45.31% |
| Annual Growth Rate | 1.19% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.71 |
ASTELLAS PHARMA UNSP.ADR - Net Assets Trend (2022–2025)
This chart illustrates how ASTELLAS PHARMA UNSP.ADR's net assets have evolved over time, based on quarterly financial data. Also explore ASTELLAS PHARMA UNSP.ADR total assets for the complete picture of this company's asset base.
Annual Net Assets for ASTELLAS PHARMA UNSP.ADR (2022–2025)
The table below shows the annual net assets of ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. For live valuation and market cap data, see ASTELLAS PHARMA UNSP.ADR stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €1.51 Trillion ≈ $1.77 Trillion |
-5.18% |
| 2024-03-31 | €1.60 Trillion ≈ $1.87 Trillion |
+5.84% |
| 2023-03-31 | €1.51 Trillion ≈ $1.76 Trillion |
+3.26% |
| 2022-03-31 | €1.46 Trillion ≈ $1.71 Trillion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ASTELLAS PHARMA UNSP.ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €740.94 Billion | 48.96% |
| Other Components | €772.32 Billion | 51.04% |
| Total Equity | €1.51 Trillion | 100.00% |
ASTELLAS PHARMA UNSP.ADR Competitors by Market Cap
The table below lists competitors of ASTELLAS PHARMA UNSP.ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Banco de Chile
SN:CHILE
|
$19.56 Billion |
|
Merck KGaA
XETRA:MRK
|
$19.57 Billion |
|
Helvetia Holding AG
SW:HELN
|
$19.58 Billion |
|
MTU Aero Engines AG
XETRA:MTX
|
$19.58 Billion |
|
Varun Beverages Limited
NSE:VBL
|
$19.55 Billion |
|
Dupont De Nemours Inc
NYSE:DD
|
$19.54 Billion |
|
Jiangsu Zhongtian Technology Co Ltd
SHG:600522
|
$19.50 Billion |
|
Equifax Inc
NYSE:EFX
|
$19.49 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ASTELLAS PHARMA UNSP.ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,595,988,000,000 to 1,513,255,000,000, a change of -82,733,000,000 (-5.2%).
- Net income of 50,747,000,000 contributed positively to equity growth.
- Dividend payments of 128,993,000,000 reduced retained earnings.
- Share repurchases of 6,960,000,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €50.75 Billion | +3.35% |
| Dividends Paid | €128.99 Billion | -8.52% |
| Share Repurchases | €6.96 Billion | -0.46% |
| Other Changes | €2.47 Billion | +0.16% |
| Total Change | €- | -5.18% |
Book Value vs Market Value Analysis
This analysis compares ASTELLAS PHARMA UNSP.ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €799.26 | €12.90 | x |
| 2023-03-31 | €839.26 | €12.90 | x |
| 2024-03-31 | €890.07 | €12.90 | x |
| 2025-03-31 | €845.25 | €12.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ASTELLAS PHARMA UNSP.ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.65%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 2.21x
- Recent ROE (3.35%) is below the historical average (4.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 8.50% | 9.57% | 0.56x | 1.60x | €-21.94 Billion |
| 2023 | 6.55% | 6.50% | 0.62x | 1.63x | €-52.08 Billion |
| 2024 | 1.07% | 1.06% | 0.45x | 2.24x | €-142.55 Billion |
| 2025 | 3.35% | 2.65% | 0.57x | 2.21x | €-100.58 Billion |
Industry Comparison
This section compares ASTELLAS PHARMA UNSP.ADR's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $20,487,092,333
- Average return on equity (ROE) among peers: 15.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ASTELLAS PHARMA UNSP.ADR (YPHA) | €1.51 Trillion | 8.50% | 1.21x | $19.55 Billion |
| Bayer AG NA (BAYN) | $47.52 Billion | 8.61% | 1.66x | $36.43 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $463.79 Million | 3.71% | 0.64x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $19.52 Billion | 19.03% | 0.35x | $10.04 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| GRIFOLS ADR 1/2/EO-50 (G0F) | $8.61 Billion | 1.82% | 1.49x | $4.21 Billion |
| Grifols S.A (G0FB) | $3.73 Billion | 14.63% | 1.72x | $4.42 Billion |
| GSK PLC SP. ADR/2 NEW (GS70) | $12.79 Billion | 38.52% | 3.61x | $101.34 Billion |
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | $1.00 Billion | 32.83% | 0.62x | $8.31 Billion |
| Sanofi (SNW2) | $59.11 Billion | 4.75% | 0.91x | $105.72 Billion |
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more